Aktis Oncology (NASDAQ:AKTS) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $31.00 price objective on the technology company’s stock.

Other equities research analysts have also issued reports about the company. TD Cowen initiated coverage on Aktis Oncology in a research report on Tuesday. They issued a “buy” rating on the stock. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $31.67.

Aktis Oncology Trading Down 4.9%

NASDAQ AKTS opened at $20.90 on Tuesday. Aktis Oncology has a 1 year low of $18.52 and a 1 year high of $29.16.

Insider Buying and Selling at Aktis Oncology

In other news, Director Ecor1 Capital, Llc bought 2,222,222 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $39,999,996.00. Following the acquisition, the director owned 4,348,658 shares of the company’s stock, valued at approximately $78,275,844. The trade was a 104.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the transaction, the insider directly owned 10,260,064 shares in the company, valued at approximately $184,681,152. This represents a 12.17% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 6,117,776 shares of company stock worth $110,119,968.

Trending Headlines about Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Several major firms initiated coverage with bullish ratings and high price targets — Bank of America (Buy, $34 PT), Leerink Partners (Outperform, $31 PT), and JPMorgan (Overweight, $30 PT) — implying 43–63% upside vs. the current price, giving institutional validation to AKTS’s strategy and growth potential.
• Positive Sentiment: TD Cowen started coverage with a Buy, highlighting Aktis’s differentiated miniprotein radiopharma platform and projecting multi‑billion dollar sales potential; this initiation is also covered in TipRanks commentary. AKTS initiated with bullish view at TD Cowen — The Fly TipRanks coverage
• Positive Sentiment: Leerink and JPMorgan notes are summarized in market wire coverage, reinforcing the consensus bullish view from new analysts. Leerink/JPMorgan coverage — Benzinga
• Neutral Sentiment: Short-interest reports for early February show “0 shares” and NaN changes — likely data errors or reporting anomalies; current filings do not provide reliable evidence of elevated short pressure or a squeeze scenario.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.